

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information if it does not display a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/498.704
--------------------	------------

09/498.704

Filing Date	02/07/2000
-------------	------------

02/07/2000

First Named Inventor	Paul S. Uster
----------------------	---------------

Paul S. Uster

Group Art Unit	1616
----------------	------

1616

Examiner Name	Unknown
---------------	---------

Unknown

Attorney Docket Number	5325-0162.30
------------------------	--------------

5325-0162.30

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Krisha

Date
Considered

13/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)



ATTY. DOCKET N
5325-0162.30

SERIAL NO.
09/498,704

RECEIVED

NOV 30 2000

APPLICANT

Uster, et al.

TECH CENTER 1600/2803

FILING DATE

February 7, 2000

GROUP

1615

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
W	WO 96/25147	08/22/96	PCT	—	—	
	WO 99/30561	06/24/99	PCT	—	—	
	WO 00/43045	07/27/00	PCT	—	—	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

W	Harrington, K., et al., "Stealth liposome encapsulated iododeoxyuridine (SLIUDR) for targeted radiosensitisation in xenograft tumours" <i>British Journal of Cancer</i> vol. 78 suppl. 2 pp. 35 abstract# P28 (1998).

EXAMINER

hsh

DATE CONSIDERED

9/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.
5325-0162.30

SERIAL NO.
09/498,704

RECEIVED

APPLICANT

Uster, et al.

MAY 16 2000

FILING DATE

February 7, 2000

GROUP

1676

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
W	4,942,226	07/17/90	Saari	—	—	
	5,077,034	12/31/91	Kassis et al.	—	—	
	5,223,263	06/29/93	Hostetler et al.	—	—	
J	5,728,684	03/17/98	Cheng et al.	—	—	
	5,811,073	09/22/98	Kassis et al.	—	—	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
W	5058879 A	03/09/93	JP	—	—	Derwent abstract only	
W	95/15154	06/08/95	PCT	—	—		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

W	Atcher, R.W., et al., "Halogenated Pyrimidines as Radiosensitizers for High-LET Radiation" <i>Radiation Research</i> 117:351-355 (1989).
	Epstein, A.H., et al., "Tumour Radiosensitization with the Halogenated Pyrimidines 5'-bromo- and 5'-iododeoxyuridine" <i>BJR Supplement</i> 24:209-214 (1992).
	Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , Ninth Edition, Hardman, et al. (eds), McGraw-Hill, New York, pp. 1247-1248 (1996).
	Hofer, K.G., "Nouvelles Et Travaux" <i>Bull Cancer (Paris)</i> 67(3):343-353 (1980).
	Mori, A., et al., "Immunotargeting of Liposomes Containing Lipophilic Antitumor Prodrugs" <i>Pharmaceutical Research</i> 10(4):507-514 (1993).
	Mori, A., et al., "Characterization of Organ-specific Immunoliposomes for Delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model" <i>Cancer Chemother Pharmacol</i> 35:447-456 (1995).



✓	Scherphof, G.L., et al., "Lipid Flow Phenomena Between Liposomes, Lipoproteins and Cell Membranes; Applications in Drug Delivery" <i>Liposome Dematics</i> , Braun-Falco, Kortling and Maibach (eds), Springer Verlag: Berlin, pp. 11-19 (1992).
	Scherphof, G.L., et al., "Liposomes in Chemo- and Immunotherapy of Cancer" <i>Lipids</i> 22(11):891-896 (1987).
	Schwendener, R.A., et al., "5'-O-Palmitoyl- and 3',5'-O-Dipalmitoyl-5-Fluoro-2'-Deoxyuridine - Novel Lipophilic Analogues of 5'-Fluoro-2'-Deoxyuridine: Synthesis, Incorporation into Liposomes and Preliminary Biological Results" <i>Biochemical and Biophysical Research Communications</i> 126(2):660-666 (1985).
	Schwendener, R.A., "The Preparation of Large Volumes of Homogeneous, Sterile Liposomes Containing Various Lipophilic Cytostatic Drugs by the Use of a Capillary Dialyzer" <i>Cancer Drug Delivery</i> 3(2):123-129 (1986).
✓	Shenoy, M.A. and Singh, B.B., "Chemical Radiosensitizers in Cancer Therapy" <i>Cancer Investigation</i> 10(06):533-551 (1992).
	Smolin, G., et al., "Idoxuridine-Liposome Therapy for Herpes Simplex Keratitis" <i>American Journal of Ophthalmology</i> 91:220-225 (1981).
	Supersaxo, A., et al., "The Antitumour Effect of Lipophilic Derivatives of 5-fluoro-2'-deoxyuridine Incorporated into Liposomes" <i>J Microencapsulation</i> 5(1):1-11 (1988).
	Van Borssum Waalkes, M., et al., "In-vitro Stability and Cytostatic Activity of Liposomal Formulations of 5-fluoro-2'-deoxyuridine and its Diacylated Derivatives" <i>Biochimica et Biophysica Acta</i> 1148:161-172 (1993).
	Van Borssum Waalkes, M., et al., "In vivo Distribution and Antitumour Activity of Liposomal 3', 5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine" <i>J Microencapsulation</i> 9(3):335-346 (1992).
	Van Borssum Waalkes, M., <i>Lipophilic Derivatives of 5-Fluoro-2'-Deoxyuridine as Liposomal Anticancer Agents</i> pp. 7-159 (1992).
	Van Borssum Waalkes, M. and Scherphof, G.L., "Liposome-Incorporated 3', 5'-O-Dipalmitoyl-5-Fluoro-2'-Deoxyuridine as a Slow-Release Anti-Tumor Drug Depot in Rat Liver Macrophages" <i>Selective Cancer Therapeutics</i> 6(1):15-22 (1990).
✓	Van Borssum Waalkes, M., et al., "Toxicity of Liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in Mice" <i>Anti-Cancer Drug Design</i> 13:291-305 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.